Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sizhou Feng

Showing results (131-140 of 219) with videos related to

Pageof 22
Sort By:
European Journal of Haematology|January 4, 2023
Herombopag promotes platelet engraftment and decreases platelet transfusion after allogeneic hematopoietic stem cell transplantationXinhui Zheng, Haixiao Zhang, Wenwen Guo, et al.
Frontiers in Cellular and Infection Microbiology|March 19, 2026
Who is at risk? Clinical features and a predictive model for 30-day mortality in hematologic patients with enterococcal bloodstream infectionNuobing Yang, Sisi Zhen, Tingting Zhang, et al.
Frontiers in Oncology|April 10, 2023
Venetoclax plus hypomethylating agents versus intensive chemotherapy for hematological relapse of myeloid malignancies after allo-HSCTZhangjie Chen, Sisi Zhen, Tingting Zhang, et al.
British Journal of Haematology|May 9, 2023
Outcomes of allogeneic or autologous stem cell transplantation followed by maintenance chemotherapy in adult patient with B-ALL in CR1 with no detectable minimal residual diseaseMengnan Lv, Liangyi Liu, Yi He, et al.
Frontiers in Immunology|September 2, 2024
Comparison of hematopoietic stem cell transplantation and repeated intensified immunosuppressive therapy as second-line treatment for relapsed/refractory severe aplastic anemiaLining Zhang, Jianping Li, Weiru Liang, et al.
Frontiers in Immunology|March 27, 2025
Immune reconstitution of human cytomegalovirus-specific T lymphocytes after allogeneic hematopoietic stem cell transplantation and their predictive role in reactivationYuanqi Zhao, Sisi Zhen, Jiali Wang, et al.
Annals of Hematology|June 22, 2024
Prophylactic therapy using epigenetic agents for RUNX1::RUNXT1-positive high-risk AML after Allo-HSCTWenwen Guo, Haixiao Zhang, Yawei Zheng, et al.
Transplantation and Cellular Therapy|May 21, 2021
Moderate to Severe Marrow Fibrosis As a More Advanced Risk Factor for MDS and MDS-AML Patients With Excess of Blasts Receiving Allogeneic Hematopoietic Stem Cell TransplantationJiali Wang, Qianqian Wang, Haixiao Zhang, et al.
British Journal of Haematology|December 16, 2024
Increasing the dose of recombinant human thrombopoietin can enhance platelet engraftment after allogeneic haematopoietic stem cell transplantation: A NICHE cohort studyDan Feng, Qingzhen Liu, Hongye Gao, et al.
Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi|August 26, 2015
[Outcomes of adults with Ph-negative B-cell acute lymphoblastic leukemia after autologous hematopoietic stem cell transplantation and the significance of minimal residual disease]Zhe Ding, Mingzhe Han, Shulian Chen, et al.
Pageof 22

Showing results (131-140 of 219) with videos related to

Sort By:
Pageof 22
European Journal of Haematology|January 4, 2023
Herombopag promotes platelet engraftment and decreases platelet transfusion after allogeneic hematopoietic stem cell transplantationXinhui Zheng, Haixiao Zhang, Wenwen Guo, et al.
Frontiers in Cellular and Infection Microbiology|March 19, 2026
Who is at risk? Clinical features and a predictive model for 30-day mortality in hematologic patients with enterococcal bloodstream infectionNuobing Yang, Sisi Zhen, Tingting Zhang, et al.
Frontiers in Oncology|April 10, 2023
Venetoclax plus hypomethylating agents versus intensive chemotherapy for hematological relapse of myeloid malignancies after allo-HSCTZhangjie Chen, Sisi Zhen, Tingting Zhang, et al.
British Journal of Haematology|May 9, 2023
Outcomes of allogeneic or autologous stem cell transplantation followed by maintenance chemotherapy in adult patient with B-ALL in CR1 with no detectable minimal residual diseaseMengnan Lv, Liangyi Liu, Yi He, et al.
Frontiers in Immunology|September 2, 2024
Comparison of hematopoietic stem cell transplantation and repeated intensified immunosuppressive therapy as second-line treatment for relapsed/refractory severe aplastic anemiaLining Zhang, Jianping Li, Weiru Liang, et al.
Frontiers in Immunology|March 27, 2025
Immune reconstitution of human cytomegalovirus-specific T lymphocytes after allogeneic hematopoietic stem cell transplantation and their predictive role in reactivationYuanqi Zhao, Sisi Zhen, Jiali Wang, et al.
Annals of Hematology|June 22, 2024
Prophylactic therapy using epigenetic agents for RUNX1::RUNXT1-positive high-risk AML after Allo-HSCTWenwen Guo, Haixiao Zhang, Yawei Zheng, et al.
Transplantation and Cellular Therapy|May 21, 2021
Moderate to Severe Marrow Fibrosis As a More Advanced Risk Factor for MDS and MDS-AML Patients With Excess of Blasts Receiving Allogeneic Hematopoietic Stem Cell TransplantationJiali Wang, Qianqian Wang, Haixiao Zhang, et al.
British Journal of Haematology|December 16, 2024
Increasing the dose of recombinant human thrombopoietin can enhance platelet engraftment after allogeneic haematopoietic stem cell transplantation: A NICHE cohort studyDan Feng, Qingzhen Liu, Hongye Gao, et al.
Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi|August 26, 2015
[Outcomes of adults with Ph-negative B-cell acute lymphoblastic leukemia after autologous hematopoietic stem cell transplantation and the significance of minimal residual disease]Zhe Ding, Mingzhe Han, Shulian Chen, et al.
Pageof 22